Haoyue Care(SH:605009) Tianfeng Securities·2025-10-10 07:13Investment Rating - The report maintains a "Buy" rating for the company with a target price not specified [5] Core Views - The company reported a revenue of 800 million in Q2 2025, representing a 26% year-on-year increase, while the net profit attributable to the parent company was 60 million, down 47% year-on-year [1] - For the first half of 2025, the company achieved a revenue of 1.8 billion, up 34% year-on-year, with a net profit of 150 million, down 23% year-on-year [1] - The revenue growth is attributed to the consolidation of Hubei Sibao [1] - The company's product revenue breakdown shows that infant hygiene products accounted for 52.9% of total revenue, adult hygiene products 36.31%, and other products 10.79% [1] Financial Performance and Forecast - The report adjusts the profit forecast for the company, expecting net profits for 2025-2027 to be 350 million, 410 million, and 470 million respectively, with corresponding P/E ratios of 20X, 17X, and 15X [4] - The financial data indicates a projected revenue growth rate of 32.44% for 2025, followed by 10.08% and 10.73% in subsequent years [4] - The company’s EBITDA is forecasted to be 514.52 million in 2025, with a slight decline in net profit margins over the forecast period [4] Business Strategy - The company plans to focus resources on increasing online promotion efforts, enhancing its own brand development, and optimizing product structure [2] - New product innovations include easy-to-wear menstrual pants and ultra-breathable materials, which have already been launched in the market [3] - The company has established deep collaborations with major clients, including global brands and emerging domestic brands, which is expected to enhance its market presence [3]